Magen BioSciences
Biotechnology company located in 100 beaver street, suite 101, waltham, ma, united states
About Magen BioSciences
Magen BioSciences, Inc. was a biotechnology firm established in 2006, positioning itself in the pharmaceutical sector with a clear focus on dermatology. The company was founded by a distinguished group of scientists and investors, including Rich Aldrich, David Fisher, Phillip Sharp, David Shaw, Christopher Walsh, and Christoph Westphal, who brought together significant experience from academia and the biotechnology industry. Sandra Luikenhuis was also noted as being integral to the founding and growth of the company.
The firm's core business was centered on the research and development of novel pharmaceutical products to improve the health and appearance of human skin. Magen BioSciences operated on a science-driven approach, leveraging a deep understanding of the underlying biology of both normal and diseased skin to identify and develop its therapeutic agents. The company's initial efforts were aimed at addressing conditions such as psoriasis, atopic dermatitis, and acne, as well as pigmentation disorders by exploring the signaling pathways related to melanin production. A key aspect of its strategy involved an exclusive licensing agreement with Eli Lilly & Co. to develop and commercialize a pipeline of preclinical compounds for dermatologic use.
Financially, Magen BioSciences secured a total of $17.2 million in funding over two rounds. The initial seed investment in March 2006 amounted to $1.8 million, co-led by ARCH Venture Partners, TVM Capital, and Venrock Associates. This was followed by a larger Series A round of $15.4 million in April 2006, with Highland Capital Partners as the lead investor. The company's trajectory culminated on April 3, 2009, when it was acquired by Pharmaceutical Product Development (PPD), a global contract research organization, for $14.5 million in cash. This acquisition was intended to expand PPD's compound partnering program into the dermatology market, integrating Magen's dermal biology expertise and compound screening capabilities.
Source: Dealroom company dataNews
Open roles
Magen BioSciences in the Waltham ecosystem
The Magen BioSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Series A5 investors entered at this stage
Highland Capital Partners
TVM Capital Life Science- QLQVT Financial LP
Alexandria Equities
Flybridge Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Magen BioSciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Magen BioSciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.




